MARKET

AZN

AZN

AstraZeneca
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.70
-0.60
-1.09%
After Hours: 55.46 +0.76 +1.39% 19:59 11/23 EST
OPEN
54.52
PREV CLOSE
55.30
HIGH
54.71
LOW
53.33
VOLUME
13.67M
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
36.15
MARKET CAP
143.57B
P/E (TTM)
57.52
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oil Rises Past August High on Vaccine Progress, Biden Transition
Bloomberg · 59m ago
Jim Cramer worries White House transition could complicate vaccine distribution
"My bet is that the vaccine will be readily available, at least, by March," the "Mad Money" host said.
CNBC.com · 4h ago
GLOBAL MARKETS-Stocks shoot up as vaccine progress, Biden transition boost confidence
Asian stocks opened higher on Tuesday as COVID-19 vaccine progress shored up global sentiment and U.S. President-elect Joe Biden was given the go-ahead to begin his White House transition. U.S. General Services Administration chief Emily Murphy wrote in a letter to Biden on Monday that he can formally begin the hand-over process. President Donald Trump tweeted that he had told his team "do what needs to be done with regard to initial protocols," an indication he was moving toward a transition after weeks of legal challenges to the election results.
Reuters · 5h ago
Stocks Gain on Start of Formal Biden Power Shift: Markets Wrap
(Bloomberg) -- U.S. equity futures and Asian stocks climbed Tuesday after the triggering of a formal transition process to President-elect Joe Biden. The dollar dipped.S&P 500 contracts advanced after the General Service Administration acknowledged Biden as the apparent winner of the presidential election. Stocks opened higher in Japan and rose in Australia. Earlier, U.S. equities closed in the green, with tech shares lagging and small caps jumping. AstraZeneca Plc became the latest firm to deliver positive vaccine news, bolstering demand for cruise-line operators and airlines. Treasury yields extended an advance.Sentiment also was boosted after people familiar with the matter said Biden plans to nominate former Federal Reserve Chair Janet Yellen to be Treasury secretary. Gold held overnight losses, while oil fluctuated.The latest vaccine successes have added to a risk-on mood in markets. Investors have snapped up assets that could benefit from the end of lockdowns, even as the virus rages across the U.S. and Europe. Traders have also started to anticipate Congress will again deliver a spending bill to stave off the economic effects of new restrictions aimed at slowing the pathogen.A Covid-19 vaccine developed by the University of Oxford and AstraZeneca prevented a majority of people from getting the disease in a large trial and the rollout could begin next month. The vaccine stopped an average of 70% of participants from falling ill, an early analysis of the data show. The effectiveness rose to 90% for one of two regimens, close to the high bar set by Pfizer Inc. and Moderna Inc.“Having that end date on the calendar, with what looks like possibly three effective vaccines defines the bottom,” Brent Schutte, Northwestern Mutual Wealth Management Chief Investment Strategist, said on Bloomberg TV. “I think investors will come in and buy the dip, and I do think you will continue to have the rotation to those value names, small-cap names, things that are leveraged to the economic cycle.”Meanwhile, data showed U.S. business activity powered ahead in November at the fastest pace since March 2015.Here are some key events coming up:Minutes of the most recent Federal Open Market Committee meeting are due Wednesday.U.S. jobless claims, GDP and personal spending data come Wednesday.U.K. expected on Wednesday to deliver the government’s spending plans for next year.Thursday sees a policy decision and briefing from the Bank of Korea.U.S. celebrates the Thanksgiving holiday on Thursday.The week ends with Black Friday, the traditional start of the U.S. holiday shopping season.These are the main moves in markets:StocksS&P 500 futures rose 0.5% as of 9:33 a.m. in Tokyo. The S&P 500 Index climbed 0.6%.Topix index rose 2.1%.Australia’s S&P/ASX 200 Index gained 1%.Kospi index added 0.6%.Hang Seng Index contracts fell 0.2% earlier.CurrenciesThe yen traded at 104.59 per dollar, down 0.1%.The Bloomberg Dollar Spot Index dipped 0.1%.The offshore yuan was at 6.5718 per dollar, up 0.2%.The euro traded at $1.1843.BondsThe yield on 10-year Treasuries rose about one basis point to 0.87%.Australia’s 10-year bond yield rose four basis points to 0.89%.CommoditiesWest Texas Intermediate crude rose 0.2% to $43.13 a barrel.Gold was at about $1,835 an ounce, down 0.2%.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 5h ago
FOREX-Yen on slippery ground as Yellen, Trump transition news boost risk appetite
The yen was on the back foot while riskier currencies were supported on Tuesday on rising optimism following news U.S. President-elect Joe Biden is expected to tap former Federal Reserve Chair Janet Yellen as U.S. Treasury Secretary. Also underpinning the risk-on mood, President Donald Trump gave the head of the General Services Administration the go-ahead to proceed with a transition for Biden's administration despite plans to continue with legal challenges. Yellen has called for increased government spending to boost the U.S. economy out of a deep recession brought on by the coronavirus and has frequently cited growing economic inequality in the United States as a threat to America's values and its future.
Reuters · 5h ago
Jim Cramer unveils list of 'return to normalcy' stocks to buy on vaccine optimism
"I think you have to buy a couple of these vaccine winners on any weakness, although when it comes to retail, I just say buy some," the "Mad Money" host said.
CNBC.com · 6h ago
Astra Shot That Works Better In Smaller Doses Raises Questions
Bloomberg · 6h ago
Japan stocks set to trade higher amid Covid vaccine hopes; Biden picks Yellen as Treasury secretary
Investor focus on Tuesday will likely be on the continued positive momentum surrounding the race for a coronavirus vaccine.
CNBC.com · 6h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZN. Analyze the recent business situations of AstraZeneca through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZN stock price target is 59.73 with a high estimate of 69.40 and a low estimate of 52.50.
EPS
Institutional Holdings
Institutions: 949
Institutional Holdings: 425.99M
% Owned: 16.23%
Shares Outstanding: 2.62B
TypeInstitutionsShares
Increased
251
14.03M
New
180
-1.91M
Decreased
200
32.47M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Non-Executive Chairman/Independent Director
Leif Johansson
Chief Executive Officer/Executive Director
Pascal Soriot
Chief Financial Officer/Executive Director
Marc Dunoyer
Executive Vice President/Chief Compliance Officer
Katarina Ageborg
Executive Vice President/Director of Human Resources
Fiona Cicconi
Executive Vice President
Jose Baselga
Executive Vice President
Pam Cheng
Executive Vice President
Ruud Dobber
Executive Vice President
David Fredrickson
Executive Vice President
Menelas Pangalos
Executive Vice President
Iskra Reic
Executive Vice President
Leon Wang
General Counsel
Jeffrey Pott
Secretary
Adrian Kemp
Non-Executive Director
Euan Ashley
Non-Executive Director
Diana Layfield
Non-Executive Director
Marcus Wallenberg
Non-Executive Independent Director
Genevieve Berger
Non-Executive Director
Weiying Wang
Non-Executive Independent Director
Philip Broadley
Independent Director
Narayan Seshadri
Non-Executive Independent Director
Deborah DiSanzo
Non-Executive Independent Director
Graham Chipchase
Non-Executive Independent Director
Michel Demare
Non-Executive Independent Director
Deborah Eldracher
Non-Executive Independent Director
Sherilyn McCoy
Non-Executive Independent Director
Tony Mok
Non-Executive Independent Director
Nazneen Rahman
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/30/2020
Dividend USD 0.44
08/13/2020
--
Dividend USD 0.93
02/27/2020
--
Dividend USD 0.44
08/08/2019
--
Dividend USD 0.93
02/28/2019
07/26/2018
Dividend USD 0.44
08/09/2018
02/02/2018
Dividend USD 0.93
02/15/2018
07/28/2017
Dividend USD 0.44
08/09/2017
03/14/2017
Dividend USD 0.93
02/15/2017
09/08/2016
Dividend USD 0.44
08/10/2016
02/25/2016
Dividend USD 0.93
02/17/2016
07/30/2015
Dividend USD 0.44
08/12/2015
02/24/2015
Dividend USD 0.94
02/18/2015
07/31/2014
Dividend USD 0.9
08/13/2014
02/07/2014
Dividend USD 1.9
02/19/2014
08/01/2013
Dividend USD 0.9
08/14/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AZN
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AstraZeneca plc (ADR) stock information, including NASDAQ:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.